Queen Mary Innovation

Regenerate Life Science formed following positive Phase II clinical trial results in Stem Cell Therapy

16 February 2016

Magnus Life Science Limited

Regenerate Life Science formed following positive Phase II clinical trial results in Stem Cell Therapy

Magnus Life Science, the innovative company focused on building and nurturing biotech companies through a unique spin-in approach, is pleased to announce the formation of Regenerate Life Science, a regenerative medicine company which will focus on the development of new technologies to enable significant advances in cardiovascular medicine through stem cell therapy. Initial clinical studies which led to the formation of Regenerate Life Science were conducted at Barts Health NHS Trust and Queen Mary University of London. Magnus continues to work closely with both organisations who will become stakeholders in Regenerate Life Science. The company has been set up to commercially exploit the positive phase II results for a novel stem cell based therapy for the treatment of patients with either Dilated Cardiomyopathy (“DCM”) or Ischemic Heart Disease (“IHD”).

Regenerate Life Science is founded by Professors John Martin (founder and Chief Scientist at Magnus Life Science) and Anthony Mathur (Professor of Cardiology, William Harvey Research Institute and Barts Health NHS Trust).

The REGENERATE-DCM study represents the first randomised placebo-controlled trial to asses the combination of granulocyte-colony-stimulating factor (G-CSF) with adjunctive-intracoronary (IC) delivery of autologous (patient’s own) bone marrow-derived cells (BMC) to show improvements in global left ventricular ejection fraction (LVEF) in patients with dilated cardiomyopathy. At 3 months, peripheral G-CSF combined with IC BMC therapy was associated with a 5.37% point increase in LVEF which was maintained to 1 year. This was associated with changes in other clinically relevant factors including an improvement in NYHA classification, reduced NT-proBNP, improved exercise capacity and quality of life. The results for Regenerate’s phase II trial REGENERATE-IHD in ischaemic heart failure are equally positive, with further information to be made available in the second quarter of 2016.

Cardiovascular disease is the UK’s single biggest killer accounting for more than a quarter of all deaths in the UK, and is the leading cause of mortality worldwide. Nearly 15% of all male deaths in the UK are due to IHD, with 1 in 10 women also affected. IHD accounts for 155,000 fatalities each year, or 425 people each day or one every three minutes (Source:  British Heart Foundation). With an estimated economic burden of £15 billion each year for the UK and €196 billion across the EU2.

David Campbell, CEO of Magnus Life Science, said: Magnus set out in 2013 to help find, build and nurture innovative new life science companies coming out of the healthcare environment. Today we announce further proof that this new model of funding works and are pleased to have been able to form this exciting new company.  There is great expectation around the use of stem cells across a number of therapeutic areas. Our data supports the use of such an approach to treat patients with heart disease and I look forward to assisting Regenerate Life Science as the company moves through the remaining regulatory hurdles to market entry.

Michele Hill-Perkins Head of Biopharma Queen Mary Innovation, Queen Mary University of London said: This new regenerative therapy has the potential for huge impact in not only saving lives but also improving the quality of life for the patients with this debilitating disease.

Anthony Mathur, Co-founder of Regenerate Life Science, said: Firstly, I would like to thank Heart Cells Foundation who together with Barts Charity sponsored the original clinical trials. I am extremely grateful for their continued support without which we would not be able to progress this therapeutic towards the clinic. The next stage in the development of Regenerate is extremely exciting as innovation steers towards stem cell therapies in clinical application. CVD is the principle target for the health of not only the UK, but also the global population. We are experiencing such high instances of irreversible damage caused by tissue death resulting from heart failure that the problem must be rectified through the integration and use of stem cells. We aim to move forwards in our research in 2016 as we continue to progress through the clinical trial process.

Press Release 15 February 2016